Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
Longeveron’s investigational early-stage Alzheimer’s drug Lomecel-B, made from donated bone marrow, is enrolling participants for a clinical trial. Scientists have faced obstacle after obstacle…
Lack of diversity in clinical trials for Alzheimer’s and other diseases is hurting research, experts say. New data offers some solutions. New research presented…
To speed up the search for Alzheimer’s treatments and cures, researchers have built machine learning technology to identify existing drugs that could be repurposed…
There are more than 100 experimental Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due…
Phase III trials for experimental dementia-related psychosis treatment pimavanserin draw interest at AAIC; FDA begins consideration of the drug approval. As many as half…
A survey of all drugs currently in clinical trials for Alzheimer’s disease found 121 unique therapies being tested in 136 Alzheimer’s drug trials. That…